文献速递脊柱脊髓外科功能神经外科

住院与门诊电极板脊髓电刺激的全国性结局分析

Value of Inpatient Neuromodulation: A National Analysis of Paddle Spinal Cord Stimulation Outcomes.
PubMed 文献 · Neurosurgery · 2026-02-20

门诊电极板SCS对合适患者短期安全且费用更低。

要点

  • 匹配后住院与门诊电极板SCS的90天并发症和再入院率无显著差异。
  • 门诊电极板SCS对合适患者短期安全且费用更低,住院仍适用于高危患者。

核心结论

  • 门诊电极板脊髓电刺激对合适患者短期安全且费用显著低于住院。
  • 住院植入仍适用于手术团队判断的高危患者,支付政策应保留两种场景的覆盖。

研究设计与样本

  • 回顾性队列研究,使用Merative MarketScan数据(2007-2023)识别成人首次电极板脊髓电刺激植入。

主要发现

  • 89.4%患者接受门诊手术;住院患者合并症更高(Elixhauser指数1.47 vs 0.55,P<.001)。
  • 倾向评分匹配后并发症率4.76% vs 3.51%(P=.093),再入院率16.54% vs 16.88%(P=.804),均无显著差异。
  • 住院费用显著更高(差值5341.15美元,P=.001)。
  • 17年间再入院率从18%降至5%(每年-0.76%,P<.001),并发症从4%降至0%(每年-0.33%,P<.001),费用每年增加912美元(P<.001)。
  • 费用差异与年龄、保险类型和地区相关;再入院率因性别、年龄和地区而异;南部住院患者并发症风险更高(OR=3.878)。

关键数值与推荐

  • 倾向评分匹配后并发症率住院4.76% vs 门诊3.51%(P=.093)。
  • 倾向评分匹配后再入院率住院16.54% vs 门诊16.88%(P=.804)。
  • 住院较门诊费用差值5341.15美元(P=.001)。
  • 17年间再入院率每年下降0.76%(P<.001),并发症每年下降0.33%(P<.001),费用每年增加912美元(P<.001)。
  • 南部住院患者并发症风险OR=3.878;女性门诊再入院OR=1.206;北中部住院再入院OR=0.506(对比东北)。

临床怎么用

  • 对合适患者可优先选择门诊电极板脊髓电刺激植入以降低费用。
  • 高危患者仍可考虑住院植入,由手术团队个体化决策。
  • 支付方政策应兼顾住院与门诊两种场景的覆盖,以保障可及性与公平性。

局限性

  • 回顾性数据库分析可能存在编码偏倚和未测量混杂。
  • 原文未报告具体保险类型、地区等亚组分析的完整细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Spinal cord stimulation (SCS) effectively manages chronic pain and degenerative spine conditions. Paddle SCS often necessitates inpatient care because of surgical complexity, yet the impact of procedural setting on outcomes, costs, and disparities remains unclear. This study evaluates total costs, 90-day readmission and complication rates, and socioeconomic disparities in paddle SCS delivery. METHODS: Using Merative MarketScan data (2007-2023), we retrospectively identified adults undergoing initial paddle lead SCS implantation. Outcomes were total costs, 90-day readmission, and complication rates. Multivariable regression adjusted for age, sex, insurance, geographic region, surgery year, and Elixhauser comorbidity index. Propensity score matching minimized confounding, and longitudinal analyses assessed temporal outcome trends. RESULTS: Of 13 704 patients, 89.4% underwent outpatient procedures. Inpatients had higher comorbidities (Elixhauser comorbidity index: 1.47 vs 0.55, P < .001). After propensity score matching, complication (4.76% vs 3.51%, P = .093) and readmission rates (16.54% vs 16.88%, P = .804) were similar between groups, but inpatient procedures incurred significantly higher costs (difference = $5341.15, P = .001). Over 17 years, readmissions declined from 18% to 5% (-0.76% annually, P < .001), complications decreased from 4% to 0% (-0.33% annually, P < .001), yet costs rose annually by $912 ( P < .001). Cost disparities were influenced by age (-$347/year, inpatient), insurance type ($10 940 higher for outpatient high-deductible plans), and region (North Central vs Northeast: -$13 505, inpatient). Readmissions varied by sex (female odds ratio [OR] = 1.206, outpatient), age (OR = 0.982/year, inpatient), and region (North Central OR = 0.506 vs Northeast). Southern inpatient patients had higher complication risks (OR = 3.878). CONCLUSION: Outpatient paddle SCS demonstrates equivalent short-term safety at substantially lower cost for appropriately selected patients. Inpatient implantation remains appropriate for select higher-risk patients at the surgical team's discretion, and payer policies should consider preserving coverage across both settings when clinically indicated to ensure access and equity.

来源:Neurosurgery,查看原文。版权归原作者所有。

引用

  1. Jain B, Abikenari MA, Sadeghzadeh S, et al. Value of Inpatient Neuromodulation: A National Analysis of Paddle Spinal Cord Stimulation Outcomes. Neurosurgery. 2026. PMID: 41718492. doi:10.1227/neu.0000000000003959

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。